

PATENT NUMBER
6599914

6599914

O.I.P.E.	PATENT DATE
SCANNED <u>T4301</u> a.a. <u>AA</u>	JUL 29 2003

APPLICATION NO.	CONT/PRIOR	CLASS	SUBCLASS	ART UNIT	EXAMINER
09/841506		514	290	1617	Krass

TITLE: Inhibition of cytosine generation
 John Schroeder
 Willam Kreutner

TITLE: Inhibition of cytosine generation
 APPLICANT(S):

PTO-2040

[illegible]

<input type="checkbox"/> TERMINAL DISCLAIMER	DRAWINGS Sheets Drwg. <u>5</u> Figs. Drwg. <u>7</u> Print Fig. <u>NONE</u>		CLAIMS ALLOWED Total Claims <u>4</u> Print Claim for O.G. <u>1</u>	
	<input type="checkbox"/> The term of this patent subsequent to _____ (date) has been disclaimed.		NOTICE OF ALLOWANCE MAILED <u>3-18-03</u>	
<input type="checkbox"/> The term of this patent shall not extend beyond the expiration date of U.S. Patent. No. _____ _____ _____	RECEIVED PRIMARY EXAMINER APR 18 2003 <u>[Signature]</u> <u>03/03</u> (Primary Examiner) (Date)		ISSUE FEE <u>W</u> Amount Due <u>1,800</u> Date Paid <u>5-29-03</u>	
	<input type="checkbox"/> The terminal _____ months of this patent have been disclaimed. _____ _____ (Legal Instruments Examiner) (Date)		ISSUE BATCH NUMBER _____	
WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 368. Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.				

FILED WITH: ☐ DISK (CRF) ☐ FICHE ☐ CD-ROM
(Attached in pocket on right inside line)

ISSUE 11

Drawing

CIP2146
Argentum Pharmaceuticals v. Cipla Ltd.
IPR2017-00807

PATENT APPLICATION



09841506



INITIALS

MAY 1 0145

CONTENTS

Date Received
(Incl. C. of M.)
or
Date Mailed

Date Received
(Incl. C. of M.)
or
Date Mailed

1. Application _____ papers.	42.	
4/3/02 2. <i>Ly 3mo</i>	43.	
3. <i>Amend A</i>	44.	
4. <i>IDS</i>	45.	
10/28 5. <i>Non Resp Amend</i>	46.	
6. <i>Response</i>	47.	
7. <i>Ext (imo)</i>	48.	
8. <i>IDS</i>	49.	
9. <i>Int Exam Exam</i>	50.	
10/11 10. <i>Amend B Notice</i>	51.	
11. <i>Formal Drawings (5 shs) set</i>	52.	
12.	53.	
13.	54.	
14.	55.	
15.	56.	
16.	57.	
17.	58.	
18.	59.	
19.	60.	
20.	61.	
21.	62.	
22.	63.	
23.	64.	
24.	65.	
25.	66.	
26.	67.	
27.	68.	
28.	69.	
29.	70.	
30.	71.	
31.	72.	
32.	73.	
33.	74.	
34.	75.	
35.	76.	
36.	77.	
37.	78.	
38.	79.	
39.	80.	
40.	81.	
41.	82.	

PATENT APPLICATION SERIAL NO. 09-841506

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

04/27/2001 SZEWDIE1 00000046 190365 09841506
01 FC:101 710.00 CH

04/27/2001 SZEWDIE1 00000070 190365 09841506
01 FC:102 240.00 CH

PTO-1556
(5/87)

*U.S. GPO: 2000-488-987/38595



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

[illegible]

CONFIRMATION NO. 5627

SERIAL NUMBER 09/841,506	FILING DATE 04/24/2001 RULE	CLASS 514	GROUP ART UNIT 1646	ATTORNEY DOCKET NO. AL01143K
APPLICANTS Robert P. Schleimer, Baltimore, MD; John Schroeder, Baltimore, MD; William Kreutner, West Paterson, NJ;				
** CONTINUING DATA *****				
** FOREIGN APPLICATIONS *****				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 06/16/2001				
Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance Verified and Acknowledged Examiner's Signature _____ Initials _____	STATE OR COUNTRY MD	SHEETS DRAWING 5	TOTAL CLAIMS 9	INDEPENDENT CLAIMS 6
ADDRESS 24265				
TITLE Inhibition of cytokine generation				
FILING FEE RECEIVED 950	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:			
<input type="checkbox"/> All Fees		<input type="checkbox"/> 1.16 Fees (Filing)		
<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)		<input type="checkbox"/> 1.18 Fees (Issue)		
<input type="checkbox"/> Other _____		<input type="checkbox"/> Credit		

Express Mail Label No. EL403237585US

Date April 24, 2001

PTO/SB/17 (09-00)

Approved for use through 10/31/2002. OMB 0851-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL
for FY 2001**

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 950.00)

Complete If Known

Application Number	To Be Assigned
Filing Date	April 24, 2001
First Named Inventor	Schleimer, et al
Examiner Name	To Be Assigned
Group Art Unit	To Be Assigned
Attorney Docket No.	AL01143K

METHOD OF PAYMENT

- 1.
- ☒
- The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number: 19-0365
Deposit Account Name: Schering-Plough Corporation

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17☐ Applicant claims small entity status. See 37 CFR 1.27

- 2.
- ☐
- Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	\$710.00
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$ 710.00)

2. EXTRA CLAIM FEES

Total Claims: 9 -20** = -0- X -0- = -0-
Independent Claims: 6 -3** = 3 X \$80.00 = \$240.00
Multiple Dependent: ☐ = ☐

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
109	80	209	40	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 240.00)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	800	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
128	240	128	240	Submission of Information Disclosure Stmt.	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
148	710	248	355	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Name (Print/Type) THOMAS D. HOFFMAN

Registration No. (Attorney/Agent) 28,221

Complete (if applicable)

Telephone (908) 298-5037

Signature

Thomas D. Hoffman

Date

April 24, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name

Signature

Date

Attorney Docket Number AL01143K

PATENT APPLICATION COVER SHEET

INHIBITION OF CYTOKINE GENERATION

INVENTORS:

ROBERT P. SCHLEIMER, a citizen of the United States, residing at
704 Stags Head Road, Baltimore, Maryland 21286, U.S.A.

JOHN SCHROEDER, a citizen of the United States, residing at 47
Dunmore Road, Baltimore, Maryland 21228, U.S.A.

WILLIAM KREUTNER, a citizen of the United States, residing at 18
Woodland Drive, West Paterson, New Jersey 07424, U.S.A.

ASSIGNEE: SCHERING CORPORATION

"Express Mail" Label No. EL403237585US
Date of Deposit: April 24, 2001

Thomas D. Hoffman
Schering-Plough Corporation
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
Telephone: (908) 298-5037
Fax: (908) 298-5388

INHIBITION OF CYTOKINE GENERATION

BACKGROUND OF THE INVENTION

The present invention relates to methods of using desloratadine to inhibit generation of pro-inflammatory cytokines, e.g., IL-4 and IL-13.

Mast cells and basophils play a role in allergic and inflammatory diseases.

- 5 These cells produce a wide variety of mediators such as prostaglandins, e.g., prostaglandin D₂, leukotrienes, e.g., leukotriene C₄ cytokines and histamine. Cytokines are polypeptides secreted by cells that affect the function of other cells. Cytokines, including interleukins, differ widely in the types of cells affected and in biological activities exhibited. Desloratadine, a non-sedating antihistamine, is
- 10 disclosed by Lippert, U., et al, *Experimental Dermatology*, 1995, Vol. 4, 272-276 to be active *in vitro* in inhibiting the release of the cytokines IL-6 by up to 40% and IL-8 by up to 50% from human mast and basophilic cell lines. Human Fc ϵ RI⁺ cells play a considerable pro-inflammatory role through the release of histamine, tryptase and chymase. However, since human mast and basophilic cell lines are
- 15 defective in signaling through the high affinity immunoglobulin-E(IgE) receptor, Fc ϵ RI, it is difficult to predict what effect, if any, desloratadine has on the IgE-mediated release of IL-6 and IL-8. . S. Molet, et al., *Clinical and Experimental Allergy*, 1997, Vol. 27, pages 1167-1174 disclose that desloratadine reduces histamine-induced release of IL-6 and IL-8 in an *in vitro* study in endothelial cells.
- 20 Kleine-Tebbe, J., et al, *J. Allergy Clin. Immunol.* 1994, Vol. 93, No. 2, pages 494-500 disclose that desloratadine inhibits IgE- and non-IgE-mediated histamine release in an *in vitro* study in human basophilic leukocyte cells.

- Human basophils are a major source of the cytokines, IL-4 and IL-13 that
- 25 are produced *in vitro* in mixed leukocyte cultures. Production of IL-4 and IL-13 by basophils may play a role in modulating a variety of activities that are involved in the pathogenesis of allergic inflammatory conditions. For example, IL-4 and IL-13 each induce secretion of IgE- and IgG-4 by human B-cells. (See Schroeder, J.T., "The role of basophil-cytokine networks in asthma." In *Asthma and Allergic*
- 30 *Diseases: Physiology, Immunopharmacology, and Treatment*, Editors: G. Marone,

K.F. Austen, ST Holgate, A.B. Kay, L.M. Lichtenstein, Academic Press, San Diego, 75-84, 1998a). However, there is no information on the effect of desloratadine on the generation of cytokines such as IL-4 and IL-13 in basophils or any other cell types. One study by Gibbs, et al. Naunyn Schmiedeberg Arch. Pharmacol, 1998, Vol. 357: 573-578 reports moderate (50%) inhibition of IL-4 and IL-13 secretion *in vitro* in basophilic cells using relatively high concentrations of terfenadine, a non-sedating antihistamine. This study did not test whether the terfenadine concentrations used were toxic. The FDA has withdrawn the two terfenadine NDAs because of the finding that terfenadine was no longer safe for cardiac reasons for use in treating seasonal allergic rhinitis. (Federal Register, October 5, 1998, Vol. 63, page-53444).

There is a need for a safe, effective therapy to inhibit secretion of pro-inflammatory cytokines such as IL-4 and IL-13 to treat disease states, for example, allergic and/or inflammatory conditions.

SUMMARY OF THE INVENTION

The present invention provides a method of inhibiting generation of IL-4 and IL-13 in a human patient in need of such inhibiting which comprises administering to such a patient an effective amount of desloratadine.

Typically, IL-4 and IL-13 is generated from human basophils as well as other cells, e.g., human B-cells.

The present invention also provides a method of inhibiting generation of IL-4 and IL-13 from human basophils in a patient exhibiting the symptoms of an allergic and/or inflammatory condition which comprises administering to such a patient an amount of desloratadine effective to inhibit the generation of IL-4 and IL-13 and to concurrently treat the symptoms of such an allergic and/or inflammatory conditions.

The present invention also provides a method of blocking generation of pro-inflammatory cytokines in a patient in need of such blocking which comprises administering to such a patient an effective amount of desloratadine.

5 The present invention also provides a method of inhibiting secretion of pro-inflammatory cytokines from human basophils in a patient in need of such inhibiting which comprises administering to such a patient an effective amount of desloratadine.

10 The preferred pro-inflammatory cytokines are IL-4 and IL-13.

15 The patients in need of such inhibiting are those having symptoms of allergic/inflammatory conditions of the airway passages, skin, eyes and intestinal tract.

20 The present invention also provides a method of treating a patient exhibiting the symptoms of allergic/inflammatory conditions of the skin, eyes, intestinal tract, and/or upper and lower airway passages which comprises administering to such a patient an effective amount of desloratadine.

25 The patients in need of such inhibiting are those having symptoms of an allergic and/or inflammatory condition of the skin, eyes, intestinal tract, and/or the upper and lower airway passages.

30 The present invention also provides a method of treating a disease state that has an allergic component and an inflammatory component which comprises administering to a patient in need of such treatment an amount of desloratadine effective to produce an anti-inflammatory effect.

35 The present invention also provides a method of treating and/or preventing allergic asthma and inhibiting secretion of IL-4 and IL-13 in a patient in need of such treating which comprises administering to such a patient an effective amount of desloratadine.

The present invention also provides a method of treating and/or preventing allergic rhinitis and inhibiting secretion of IL-4 and IL-13 in a patient in need of such treating which comprises administering to such a patient an effective amount
5 of desloratadine.

The present invention also provides a method of treating and/or preventing atopic dermatitis and inhibiting secretion of IL-4 and IL-13 in a patient in need of such treating which comprises administering to such a patient an effective amount
10 of desloratadine.

The present invention also provides a method of treating and/or preventing urticaria and inhibiting secretion of IL-4 and IL-13 in a patient in need of such treating which comprises administering to such a patient an effective amount of
15 desloratadine.

The present invention also provides a method of treating IL-4 and IL-13 mediated disease states in a patient in need of such treating which comprises administering to such patients an effective amount of desloratadine to inhibit
20 generation of IL-4 and IL-13.

The effective amount of desloratadine is an amount sufficient to inhibit and preferably block generation of IL-4 and IL-13 from human cells.

25 The present invention also provides a method of inhibiting generation of IL-4 and IL-13 from human basophils in a patient exhibiting the symptoms of an allergic and/or inflammatory condition of the skin, eyes, intestinal tract, and/or the upper and lower airway passages which comprises administering to such a patient an amount of desloratadine effective to inhibit the generation of IL-4 and IL-13 and
30 to concurrently treat the symptoms of such an allergic and/or inflammatory condition.

BRIEF DESCRIPTION OF THE FIGURES

5 Figures 1a and 1b illustrate the effect of desloratadine on histamine, leukotriene C₄ ("LTC₄") and IL-4 secretion by human basophils.

Figure 2 graphically illustrates the effect of desloratadine on histamine release and IL-4 secretion in response to activation by ionomycin.

10

Figure 3 graphically illustrates the effect of desloratadine on IL-13 secretion by human basophils activated by anti-IgE and ionomycin.

15

Figure 4 graphically illustrates that desloratadine inhibits IL-13 secretion from basophils activated with IL-3 and PMA.

Figures 5a, 5b, 5c and 5d graphically illustrate the inhibition of IL-4 mRNA expression in basophils pretreated with desloratadine.

20

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the methods of the present invention, we demonstrated the ability of desloratadine to inhibit the generation of IL-4 and IL-13 from human basophils while concurrently comparing its efficacy in preventing mediator release from these cells using a variety of stimuli. Desloratadine was found to be remarkably (nearly 6-7) times more potent in reducing the secretion of IL-4 and IL-13 from human basophils induced by anti-IgE than it was at inhibiting the mediators, histamine and LTC₄, released in the same culture supernatants. The cytokines, IL-4 and IL-13, were equally inhibited by desloratadine following activation with ionomycin despite the lack of an effect on the histamine release induced with ionomycin. Desloratadine had a lesser effect at inhibiting the IL-13 secreted in response to IL-3 and PMA, suggesting that the antihistamine differentially targets individual pathways of cytokine generation. Finally, there was

no evidence that desloratadine was cytotoxic, i.e., that it mediated its inhibitory effects by causing decreased cell viability. In accordance with the present invention, IL-4 mRNA accumulation was also remarkably inhibited, by as much as 80%, following pretreatment with desloratadine, suggesting that desloratadine targets signals regulating cytokine gene transcription in addition to those controlling mediator release.

The phrase "an allergic and/or inflammatory condition" means those allergic and inflammatory conditions and symptoms found on the skin, eyes, intestinal tract and/ or in the upper and lower airway passages from the nose to the lungs. Typical allergic and/or inflammatory conditions of the skin or upper and lower airway passages include seasonal and perennial allergic rhinitis, non-allergic rhinitis, asthma including allergic and non-allergic asthma, sinusitis, colds, dermatitis, especially allergic and atopic dermatitis, and urticaria and symptomatic dermographism. Typical allergic and/or inflammatory conditions of the eyes include, but are not limited to, allergic conjunctivitis. Typical allergic and/or inflammatory conditions of the intestinal tract, but are not limited to, food allergies.

The term "human" as used herein includes a male or female pediatric subject of less than 12 years of age to less than 18 years of age, a male or female pediatric subject of greater than 12 years of age to less than 18 years, and male and female adults of 18 years of age and older.

The term "pro-inflammatory cytokines" as used herein means those cytokines associated with allergic and inflammatory reactions of the skin, eyes, intestinal tract, and airway passages of humans exposed to allergens. Typically suitable pro-inflammatory cytokines include IL-3, IL-4, IL-5, IL-6, IL-8, IL-9 and IL-13.

The amount of desloratadine effective for treating or preventing allergic and inflammatory conditions of the skin or airway passages will vary with the age, sex, body weight and severity of the allergic and inflammatory condition of the patient. Typically, the amount of desloratadine effective for treating or preventing such

allergic and inflammatory conditions in an adult human of age older than 12 is in the range of about 2.5 mg/day to about 45 mg/day, preferably about 2.5 mg/day to about 20 mg/day, or about 5.0 mg/day to about 15 mg/day, or about 5.0 mg/day to about 10 mg/day, more preferably about 5.0 mg/day to about 7.5 mg/day, and
5 most preferably about 5.0 mg/day in single or divided doses, e.g., 2 x 2.5 mg/day, or a single dose of 5.0 mg/day.

Desloratadine is a non-sedating long acting histamine antagonist with potent and selective peripheral H₁-receptor antagonist activity. *In vitro* and *in vivo*
10 animal pharmacology studies have been conducted to assess various pharmacodynamic effects of desloratadine and loratadine. In assessing central nervous system ("CNS") activity in mice, desloratadine was relatively free of producing alterations in behavior, neurologic or autonomic function. The potential for desloratadine to occupy brain H₁-receptors was assessed in guinea pigs
15 following IP administration and results suggest poor access to central histamine receptors for desloratadine.

The clinical efficacy and safety of desloratadine has been documented in
20 over 3,200 seasonal allergic rhinitis patients in 4 double-blinded, randomized clinical trials. The results of these clinical studies demonstrated the efficacy of desloratadine in the treatment of adult and adolescent patients with seasonal rhinitis.

25 Efficacy endpoints in all the studies were Total Symptom Score, Total Nasal Symptom Score, Total Non-nasal Symptom Score, and Health Quality of Life (HQOL) analysis in efficacy trials. Desloratadine (5 mg once daily) significantly reduced the total symptom scores (the sum of individual scores for rhinorrhea, sneezing, congestion/stuffiness, nasal itching, itchy/burning eyes,
30 tearing, ocular redness, and itchy ears/palate). Desloratadine (5 mg) was significantly ($p < 0.01$) more effective than placebo in reducing nasal symptoms. An important efficacy endpoint analyzed in the desloratadine studies is the AM NOW total symptom score. This parameter measures the total symptom relief by

the patient after 24 hours before taking the next day dose. Statistically significant (p<0.05) reductions were maintained for the full 24 hour dosing interval over the entire 5 mg to 20 mg dosage range.

5 There were no significant differences in the effectiveness of desloratadine (over the entire 5 mg to 20 mg dosage range) across subgroups of patients defined by gender, age, or race. Desloratadine is particularly useful for the treatment and prevention of the nasal (stuffiness/congestion, rhinorrhea, nasal itching, sneezing) and non-nasal (itchy/burning eyes, tearing/watery eyes, redness
10 of the eyes, itching of the ears/palate) symptoms of seasonal allergic rhinitis, including nasal congestion, in patients in need of such treating and/ or preventing.

U.S. Patent No. 4,659,716 discloses methods of making desloratadine, pharmaceutical compositions containing it and methods of using desloratadine
15 and pharmaceutical compositions containing it to treat allergic reaction in mammals.

U.S. Patent No. 5,595,997 discloses pharmaceutical compositions containing desloratadine and methods of using desloratadine for treating and
20 preventing various disease states, e.g., allergic rhinitis.

U.S. Patent No. 6,100,274 discloses stable pharmaceutical compositions containing desloratadine suitable for oral administration to treat allergic reactions, e.g., allergic rhinitis.
25

The pharmaceutical compositions of desloratadine can be adapted for any mode of administration e.g., for oral, parenteral, e.g., subcutaneous ("SC"), intramuscular ("IM"), and intraperitoneal ("IP"), topical or vaginal administration or by inhalation (orally or intranasally). Preferably desloratadine is administered
30 orally.

Such pharmaceutical compositions may be formulated by combining desloratadine or an equivalent amount of a pharmaceutically acceptable salt

thereof with a suitable, inert, pharmaceutically acceptable carrier or diluent that may be either solid or liquid. Desloratadine may be converted into the pharmaceutically acceptable acid addition salts by admixing it with an equivalent amount of a pharmaceutically acceptable acid. Typically suitable pharmaceutically acceptable acids include the mineral acids, e.g., HNO_3 , H_2SO_4 , H_3PO_4 , HCl , HBr , organic acids, including, but not limited to, acetic, trifluoroacetic, propionic, lactic, maleic, succinic, tartaric, glucuronic and citric acids as well as alkyl or arylsulfonic acids, such as p-toluenesulfonic acid, 2-naphthalenesulfonic acid, or methanesulfonic acid. The preferred pharmaceutically acceptable salts are trifluoroacetate, tosylate, mesylate, and chloride. Desloratadine is more stable as the free base than as an acid addition salt and the use of the desloratadine free base in pharmaceutical compositions of the present invention is more preferred. See U.S. Patent No. 6,100,274.

Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 2.5 to about 95 percent active ingredient preferably from about 2.5 to about 20 percent, more preferably from about 2.5 to about 10 percent, or from about 2.5 to about 5 percent and most preferably 5 percent of the active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Solid form preparations may be converted into liquid preparations shortly before use for either oral or administration. Parenteral forms to be injected intravenously, intramuscularly or subcutaneously are usually in the form of sterile solutions and may contain tonicity agents (salts or glucose), and

buffers. Opacifiers may be included in oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration. The liquid form preparations may comprise the same ranges of active ingredient is as used in solid form preparations.

5

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g., nitrogen.

10

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

15

The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

20

Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.

25

Further, desloratadine may be administered in association with therapeutically effective amounts of steroids, e.g. mometasone furoate, beclomethasone dipropionate or fluticasone propionate, leukotriene inhibitors, e.g., montelukast sodium or zafirlukast, and/or an upper airway passage decongestant including, but not limited to phenylephedrine, pseudoephedrine and

30

phenylpropanolamine or pharmaceutically acceptable salts thereof, in accordance with the dosing levels known to those skilled in the art and as described in the *Physicians' Desk Reference*. The use of the upper airway passage decongestant, pseudoephedrine HCl, is preferred.

EXAMPLES

MATERIALS AND METHODS

5

Special Reagents

All reagents were purchased unless otherwise noted. Piperazine-N,N'-bis-2-ethanesulfonic acid (PIPES), ionomycin, FMLP, PMA, and fetal bovine serum (FBS) from Sigma Chemical Co. (St. Louis, MO); RPMI-1640 and Iscove's modified Dulbecco's medium (IMDM) both with L-glutamine and containing 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), gentamicin, nonessential amino acids (100x) from Life Technologies, Inc., Grand Island, NY; and Percoll from Pharmacia (Piscataway, NJ). The desloratadine used in these experiments was supplied by The Schering-Plough Research Institute. A 0.1 M stock solution was made in DMSO, aliquoted, and frozen at -20°C. All pipes-containing buffers were made from stock 10X PIPES (250 mM PIPES, 1.20 M NaCl, and 50 mM KCL, pH 7.3 and stored at 4°C). Isotonic Percoll, (referred to as 100% Percoll) was made by mixing 9 parts Percoll with 1 part 10X PIPES. PAG contained one-tenth 10X PIPES, 0.003% HAS, and 0.1% D-glucose. PAG-EDTA additionally contained 4 mM EDTA. Percoll solutions used for cell isolation were all made by mixing the appropriate amounts of 100% Percoll with IX PIPES.

Cell Preparation and Culture

Mixed leukocyte suspensions containing basophils were prepared either using double-Percoll density centrifugation as described (Schroeder, et al., J. Immunol., 1994, Vol. 153: 1808, or by a combination of countercurrent elutriation and Percoll density centrifugation protocols (MacGlashan, et al., J. Immunol., 1994, Vol. 153:3006-3016). The percentages of basophils obtained using these protocols typically ranged between 5-50% and 10-30%, respectively, and were determined by counting Alcian blue positive and negative stained cells on a Spiers-Levy chamber (Gilbert and Ornstein, 1975). For some experiments, the basophils were additionally purified to >99.9% using a negative-selection protocol (Miltenyi Corp., Auburn, CA). For all experiments other than those

assessing IL-4 mRNA expression, the cells were cultured in 96-well flat-bottom microtiter plates (in duplicate) using IMDM supplemented with 5% heat-inactivated (56°C for 30 min.) FBS, 1 x non-essential amino acids, and 5 µg/ml gentamicin (C-IMDM). For the analysis of IL-4 mRNA expression, cells in C-IMDM were

5 cultured in autoclaved (RNase-free) 1.5 ml microcentrifuge tubes (see below), since this allowed for a more precise way to quantitatively isolate mRNA without the need for transferring cells from culture wells before extraction. For each condition, leukocyte suspensions containing approximately 100,000-500,000 basophils in 100 µl of C-IMDM were prewarmed to 37°C before adding 100 µl of

10 desloratadine concentrations in C-IMDM also prewarmed to 37°C. After 15 minutes preincubation, the cells were then activated by adding 50 µl of 5x (5 times the final concentration) of stimulus. It is important to note here that the concentrations of stimuli used were optimal for IL-4 generation rather than mediator release. This is particularly true for anti-IgE antibody, which has been

15 shown to induce IL-4 at concentrations 10-fold less than those causing optimal histamine release (Schroeder, et al., *ibid*). For harvesting, cultures were centrifuged and cell-free supernatants collected for mediator release and cytokine analysis, as described (Schroeder, et al., *ibid*). Histamine, LTC₄, and IL-4 were all measured in aliquots of culture supernatant taken at 4 hours. For histamine, this

20 meant taking 20-50 µl of supernatant and diluting it in 1 ml of PAG buffer containing 1.6% HClO₄. After an overnight precipitation at 4°C, the samples were assayed by automated fluorimetry (Siraganian, R.P., *Anal. Biochem.*, 1974, Vol.57:383-394). LTC₄ was measured by an in-house RIA (MacGlashan, et al., *J. Immunol.*, 1986, Vol.136:2231-2239). IL-4 protein was measured by a commercial

25 ELISA (Biosource International). Culture supernatants were harvested after 20 hours incubation for all experiments investigating the effects of desloratadine on IL-13 secretion. In some instances, IL-4 was also measured at this time point, particularly when ionomycin was used, since the kinetics for the secretion of this cytokine extend beyond 4 hours with this stimulus (Schroeder, et al., *J. Leuk. Biol.*,

30 *1998*, Vol. 63:692-698). IL-13 protein measurements were also made using a commercial ELISA (Immunotech).

RNA Isolation and Semi-Quantitative Analysis of IL-4 mRNA Expression

Cultures for the analysis of IL-4 mRNA were performed in 1.5 ml polypropylene microcentrifuge tubes, as described above. Cells were pretreated with desloratadine (10 μ M) for 15 minutes prior to activating with anti-IgE antibody (10-20 ng/ml). Total RNA was isolated using the RNeasy protocol (Qiagen Inc., Crawfordsville, TX) after 2 hours incubation, which is the time that IL-4 message expression peaks using IgE-dependent activation (Schroeder, et al., J. Immunol., 1997, Vol. 158:5448-5454). Following isopropanol precipitation, the RNA was washed with 70% ethanol and dried under vacuum. Subsequently, the RNA was resuspended in 25 μ l of diethylpyrocarbonate (DEPC)-treated water and stored at -80°C. Reverse Transcription (RT) and polymerase chain reaction (PCR) were performed with serial dilutions of RNA as previously detailed (MacGlashan, et al., J. Immunol., 1994; Vol. 152:3006-3016; Schroeder, et al., J. Immunol., 1997, Vol. 158: 5448-5454) using the GeneAmp RNA PCR kit (Perkin-Elmer Cetus, Norwalk, CT). PCR products were visualized in 3% agarose gels using ethidium bromide staining. As noted elsewhere, two distinct bands for IL-4 were observed. A dominant band was seen with a size of approximately 460 bp. The source of the smaller, fainter band is uncertain, but is thought to be an alternatively spliced form of IL-4 (Atamas, et al., J. Immunol., 1996, Vol. 156:435-441). The two bands are routinely observed using either pure or enriched suspensions of basophils.

Figures 1a and 1b graphically illustrate the effect of desloratadine on histamine, LTC₄, and IL-4 secretion by human basophils. For Figure 1a, mixed leukocyte suspensions containing 3-55% basophils were prepared from whole blood using Percoll density centrifugation. Cells were pretreated 15 min. with the indicated concentrations of desloratadine before activating with anti-IgE antibody (10-20 ng/ml). All three products were measured using the same culture supernatants harvested after 4 hours incubation. Values are the mean \pm SEM (n=5). Control release for each product: Histamine: 40 \pm 6% of total, IL-4: 403 \pm 207 pg/10⁶ basophils, and LTC₄: 860 \pm 127 pg/10⁶ basophils. Figure 1b

shows the effect of desloratadine on histamine, LTC₄, and IL-4 secretion from human basophils, 99% purity. Control release for histamine, LTC₄, and IL-4 were 60% of total, 903 pg/10⁶ basophils, and 854 pg/10⁶ basophils, respectively.

- 5 Figure 2 illustrates the effect of desloratadine on histamine release (HR) and IL-4 secretion in response to ionomycin. Basophil suspensions of 42, 99, and 98% purity were pretreated 15 min. with 0.1, 1.0, and 10 μ M desloratadine. Cells were then activated with ionomycin (500 ng/ml) for 4 hours. Culture supernatants were harvested and assayed for histamine and IL-4 protein. Values represent the mean \pm SEM, n=3. Control levels of IL-4 were 3398, 253, and 348 pg/10⁶ basophils. Percent histamine release in the same cultures was 91, 25, and 10%, respectively.

- 15 Figure 3 illustrates the effect of desloratadine on IL-13 secretion by human basophils activated by anti-IgE or ionomycin. Basophil suspensions ranging in purity between 6-99% were pretreated 15 min. with the indicated concentrations of desloratadine. Cells were activated with either anti-IgE (10-20 ng/ml) or ionomycin (500 ng/ml). Culture supernatants were harvested after 18 hours incubation and assayed for IL-13 protein by ELISA. Values with error bars represent the mean \pm SEM, n=3. IL-13 protein in control cultures averaged 169 \pm 35 and 334 \pm 144 pg/10⁶ basophils for anti-IgE and ionomycin, respectively. Values indicated by the open circles are the mean for two experiments (control levels of IL-13 were 260 and 230 pg/10⁶ basophils).

- 25 Figure 4 graphically illustrates that desloratadine inhibits IL-13 secretion from basophils activated with IL-3 and PMA. Basophils (up to 94% purity) were prepared from whole blood using double Percoll density centrifugation and negative selection protocols. Cells were pretreated with the indicated concentrations of desloratadine before adding IL-3 (100 ng/ml) or PMA (2 ng/ml). Culture supernatants were harvested after 18 hours incubation and assayed for IL-13 protein by ELISA. Values represent the mean \pm SEM, n=3-4. The amount of

IL-13 secretion in the absence of desloratadine averaged 570 ± 142 pg/ 10^6 basophils for IL-3 activation and 216 ± 120 pg/ 10^6 basophils for PMA induction.

Figures 5a-d graphically illustrate the inhibition of IL-4 mRNA expression in basophils pretreated with desloratadine. Cells were incubated 15 min. with desloratadine ($10 \mu\text{M}$) or DMSO (1:10,000) before receiving anti-IgE (10 ng/ml) or medium alone. Total RNA was isolated after 2h and used for dilutional RT-PCR analysis to compare message expression for IL-4 and the housekeeping gene, hypoxanthine phosphoribosyl transferase (HPRT) (panel a). Densitometric analysis is shown for undiluted RNA expression (panel b). The histamine and IL-4 secretion in the supernatants after 2h are shown for comparison (panels c and d, respectively). Values represent the mean \pm SEM, $n=3$.

DISCUSSION

In the first series of experiments (See Figures 1a&1b), we demonstrated the ability of desloratadine to block IL-4 secretion from basophils triggered by anti-IgE, and compared this inhibition to that seen for histamine and LTC₄ release in the same 4h culture supernatants. As shown in Figure 1a, desloratadine dose-dependently inhibited the release of histamine and LTC₄ at concentrations between $1 \mu\text{M}$ (10^{-6} M) and $10 \mu\text{M}$ (10^{-5} M). For comparison, desloratadine was strikingly more potent against IL-4 secretion than for preformed mediator release. Cells pretreated with $1 \mu\text{M}$ to $10 \mu\text{M}$ desloratadine secreted 40% to 80% less IL-4 than cells not exposed to drug. Nearly a seven-fold greater concentration of desloratadine was necessary to cause a comparable inhibition in the release of histamine and LTC₄ by these cells. The inhibition of IL-4, unlike that seen for histamine, appeared to plateau in the micromolar range of desloratadine and then reached progressively higher values at concentrations between $1 \mu\text{M}$ and $10 \mu\text{M}$ desloratadine. As shown in Figure 1b, this effect was also evident using basophils purified to greater than 99%, indicating that desloratadine was directly affecting basophils for the inhibition of IL-4. Desloratadine also inhibited histamine from pure basophils much as it did for impure suspensions.

We tested whether desloratadine affected IL-4, histamine, and LTC₄ release from basophils activated by other stimuli. Figure 2 shows that the secretion of histamine induced by the calcium ionophore, ionomycin, was unaffected by desloratadine at concentrations of 0.1, 1.0, and 10 μ M. However, the high levels of IL-4 that were secreted in response to ionomycin stimulation were remarkably inhibited by the same concentrations of desloratadine (i.e. 0.1, 1.0 and 10 μ M). The histamine and LTC₄ made in response to FMLP stimulation was also not inhibited by desloratadine (data not shown).

Redrup, et al., *J. Immunol.*, 1998, Vol. 160:1957-1964 reported that (1) multiple stimuli induce pharmacologically distinct pathways for the generation of IL-13 in human basophils and that (2) both anti-IgE and ionomycin induced IL-13 secretion that was sensitive to the immunosuppressive drug, FK-506, suggesting that these stimuli utilize a calcineurin-dependent pathway to generate this cytokine. In the Redrup, et al study, the IL-13 made in response to IL-3 or PMA activation was unaffected by FK-506, and only protein generated in response to the phorbol ester was inhibited by PKC inhibitors. Therefore, we addressed whether the IL-13 induced by these stimuli is also differentially affected with desloratadine pretreatment. Figure 3 shows that IL-13 generated in response to either anti-IgE or ionomycin. In fact, there was remarkable similarity in the shape of the concentration-response curve of desloratadine for inhibition of IL-13 induced by either stimulus. These curves in Figure 3 were nearly identical to that seen for the inhibition of IL-4 by desloratadine as shown in Figures 1 and 2. In particular, an initial plateau was seen at 1 μ M at the level of 50-70% inhibition. Dose-dependent inhibition of IL-13 continued as desloratadine concentrations were increased up to 10 μ M. Interestingly, the response to desloratadine pretreatment was considerably different in two experiments using impure (6-11%) basophil suspensions. With these cell preparations, desloratadine was considerably less effective in preventing the IL-13 secreted in response to anti-IgE, requiring nearly 10-fold greater concentrations to produce the same IC₅₀ seen using more pure basophil suspensions. Figure 4 shows that desloratadine also inhibited the IL-13 made in response to IL-3 or PMA, albeit to a lesser extent and

with inhibition curves that appeared more log-linear. In fact, the drug inhibited IL-3-mediated IL-13 production with an IC_{50} of approximately 2 μ M, which was nearly 5-fold that necessary to inhibit the IL-13 secreted with anti-IgE or ionomycin activation. Desloratadine inhibited the IL-13 induced by PMA in similar fashion, with inhibition seen between 1 μ M and 10 μ M concentrations of drug.

Unlike histamine and LTC_4 , both of which are released from basophils within minutes after activation, IL-4 protein is first detected after 1-2 hours and IL-13 some 48 hours after activation. Therefore, it seemed possible that the kinetics of mediator release vs. cytokine production might account for the differences in their sensitivity to desloratadine, particularly if cell lysis was a factor. However, we saw no evidence that 10 μ M desloratadine, even when combined with stimulus for 18 hours, was cytotoxic, i.e., caused cell death as assessed by trypan blue exclusion in pure basophil cultures (data not shown). Cells did stain with trypan blue when cultured with 100 μ M desloratadine alone. Furthermore, histamine was detected in these cultures, indicating that this concentration of desloratadine caused cell lysis.

Finally, to investigate the possibility that desloratadine inhibits cytokine secretion from basophils by affecting the accumulation of mRNA, we examined the effect of desloratadine (10 μ M) pretreatment on the expression of IL-4 message. For these experiments, we used a dilutional RT-PCR protocol to provide a semi-quantitative analysis. Panel a of Figure 5 clearly shows that IL-4 mRNA expression was induced in cells activated with anti-IgE (lanes 8-10) relative to cells not receiving stimulus (lanes 2-4). Pretreatment with desloratadine resulted in a substantial decrease of the induced cytokine message (lanes 11-13), while having no effect on the expression of the housekeeping gene, HPRT. Panel b of Figure 5 shows the average densitometric analysis of three experiments, indicating that desloratadine pretreatment caused approximately an 80% reduction in the IL-4 message accumulated with anti-IgE activation. For comparison, desloratadine (10 μ M) also inhibited the histamine and IL-4 protein

secreted into the supernatants of these cultures, as shown in panels c and d, respectively, of Figure 5.

Our findings support the concept that the mechanisms underlying the efficacy of H1-antagonists in the treatment of allergic rhinitis extend beyond their ability to prevent histamine from binding to its H1 receptor by showing that desloratadine possesses inhibitory activity against the generation of IL-4 and IL-13 from human basophils. Others have shown that desloratadine prevents IgE-mediated histamine release and LTC₄ generation by human basophils and our results confirm these findings (See Kleine-Tebbe, et al., 1994; and Genovese, et al., *Clin. Exp. Allergy*, 1996, Vol. 27:559-567). However, in accordance with this invention, we have shown that desloratadine is remarkably (6 to 7-fold) more effective at inhibiting IL-4 and IL-13 induced by anti-IgE than it is at blocking histamine and LTC₄ release in these cultures. Interestingly, in accordance with this invention, desloratadine inhibited IL-4 and IL-13 with a dose response curve that plateaued at 1 and 10 μ M concentrations. (See Figure 1b.) This effect was not seen for mediator release and occurred only for cytokine (IL-4 and IL-13) produced in response to anti-IgE or ionomycin. While the nature of this inhibition is presently unknown, we predict that desloratadine targets at least two signals along with common pathway triggered by both stimuli. Thus, at concentrations below 1 μ M desloratadine, the inhibition may result from disruption of a signal involved only in cytokine generation, while at concentrations above 1 μ M, a second signal may also be affected, resulting in inhibition of preformed mediator release for most stimuli.

We found desloratadine to be less effective at preventing mediator release induced by IgE-independent stimuli, such as ionomycin, fmlp, and phorbol ester. In fact, we found no evidence that the histamine and/or LTC₄ released with these stimuli were inhibited by any of the desloratadine concentrations tested (data not shown). In contrast, desloratadine was quite effective in blocking the production of IL-4 induced by ionomycin and the IL-13 generated in response to either ionomycin, PMA, or IL-3. As noted above, desloratadine equally inhibited the IL-4

and IL-13 induced by ionomycin or anti-IgE with inhibition curves that plateaued at 1 and 10 μ M concentrations of drug. However, the same pattern and potency of inhibition was not observed for the inhibition of IL-13 induced by IL-3 or PMA. With regard to cytokine production, both anti-IgE and ionophore induced IL-4 and IL-13 that are inhibited by the immunosuppressive drug, FK506, suggesting that these stimuli utilize a calcium-dependent calcineurin pathway for the generation of these cytokines. However, desloratadine does not block the IL-13 made in response to IL-3 or PMA, both of which are thought to activate separate pathways. Thus, desloratadine may inhibit IgE-dependent cytokine secretion and mediator release by simply preventing changes in cytosolic calcium. This effect, however, does not fully explain why desloratadine inhibited cytokine induced by ionomycin while having no effect on mediator release. Since IgE-crosslinking and Ca^{2+} ionophores appear to activate calcineurin in basophils, it is possible that desloratadine targets a factor within pathway initiated by this phosphatase.

By using pure basophil suspensions we were able to conclude for the first time whether desloratadine mediates its inhibitory effect on basophil mediator release and cytokine production directly. We could detect no evidence, as assessed by trypan blue exclusion, that the decreased IL-4 and IL-13 secreted was accompanied by increased cell death during the 4-20 hour incubations. This was true even with 10 μ M desloratadine which caused nearly complete(>95%) inhibition of cytokine secretion. Cell lysis was observed at a concentration of 100 μ M.

In accordance with the methods of the present invention, we have demonstrated that desloratadine inhibits the accumulation of IL-4 mRNA, supporting the concept that desloratadine can negatively regulate factors important for cytokine gene transcription. Interestingly, desloratadine pretreatment resulted in nearly 80% inhibition of the IgE-mediated increase of IL-4 mRNA. However, the secretion of protein for this cytokine (IL-4) in the same cultures was below detection, and was thus inhibited >95%. Once again this may imply that desloratadine targets multiple pathways in the generation of cytokines,

affecting more than just signals important for gene transcription. In fact, it remains possible that transcription is not at all affected but that IL-4 and IL-13 mRNA is made unstable in some way and that this accounts for the inhibitory action of desloratadine. If so, the instability must be specific for cytokine mRNA, since our results demonstrated that housekeeping gene (HPRT) expression is unaffected by desloratadine.

We expect that inhibitory effects of desloratadine on cytokine generation and mediator release seen in these *in vitro* studies should translate into the clinical efficacy of desloratadine against allergic and inflammatory conditions of the skin, e.g., atopic dermatitis and urticaria, and in the eyes, e.g., allergic conjunctivitis, and in the intestinal tract, e.g., food allergies, and in the upper and lower airway passage, e.g., allergic rhinitis, especially seasonal allergic rhinitis. Given the fact IL-4 and IL-13 help regulate the synthesis of IgE, activate endothelium for VCAM-1-mediated eosinophil transmigration, and that IL-4 promotes the development of the T-helper 2 phenotype, we expect that desloratadine will mediate anti-allergic activity, not only by inhibiting mediator release, but also by blocking the generation of pro-inflammatory cytokines IL-3, IL-4, IL-5, IL-6, IL-8, IL-9 and IL-13.

CLINICAL STUDIES

The following clinical studies are designed to show that desloratadine provides combined antihistaminic and anti-allergic inflammatory effects to control both early and late phase allergic reactions and clinical symptoms on human subjects exposed to allergens or exhibiting the signs and symptoms of allergic and/or inflammatory diseases of the skin, eyes intestinal tract, and airway passages.

STUDY NO. 1**Objective**

- 5 To demonstrate that nasal allergen provocation of atopic human subjects induces systemic allergic/immunologic effects, such as, increased cytokine production by basophils and lymphocytes, and that this will be manifested *in vitro* (increased cytokine release) and *in vivo* (increase in late-phase reaction in allergen-induced skin reaction).

10

Study Design

- This will be an open-label, non-therapeutic, pilot study, involving 6 to 10 asymptomatic atopic subjects with documented histories of seasonal allergic rhinitis (and possibly allergic asthma) who will be challenged nasally with allergen on 3 consecutive days.

15

- Blood specimens will be collected 3 days before beginning the nasal challenges, daily prior to each challenge, and one week after the first challenge. Basophils and lymphocytes will be isolated using standard Percoll gradient techniques and their RNA will be extracted and tested using a real time PCR assay with primers for IL-3, IL-4, IL-5, IL-6, IL-9 IL-13, IL-5 and RANTES.

20

- The mRNA for these cellular products will be quantitated by comparison to the PCR product of a housekeeping gene (GAPDH). Leukocyte differential, and total eosinophil and basophil counts will be used to assess the potential effect of changes in cell numbers on allergen-induced changes in cytokine/chemokine mRNA.

25

- Dose-titrated allergen-induced skin wheal reaction testing will be done at the time of initial blood drawing above (i.e., 3 days prior to the first nasal allergen challenge) and one week after the last nasal allergen challenge.

30

Nasal symptom severity scores will be monitored during each nasal allergen provocation day. It is expected that induction of cytokine transcription will correlate to worsening nasal symptomatology.

5 **Primary Endpoint:**

Based on *in vitro* data, the expected primary outcome should be allergen-induced increases in inflammatory cells and up-regulation of IL-4 and IL-13 transcription in the skin biopsy tissue.

Secondary Endpoints:

- 10 Changes from baseline in peripheral leukocytes, including eosinophils, basophils and lymphocytes.

Changes from baseline in cytokine production by leukocytes.

- 15 Change from baseline in the size of the allergen-induced skin wheal late phase reaction.

Correlation of the above changes with clinical symptomatology.

20 **STUDY NO. 2**

Objective

Identification of the biochemical and clinical effects of the anti-allergic and anti-inflammatory properties of desloratadine.

25

- A study of the effects of desloratadine on the induction of peripheral blood leukocyte cytokines by nasal allergen provocation in atopic human subjects: a preliminary clinical study to demonstrate that desloratadine provides combined antihistaminic and anti-allergic effects to control early and late phase allergic reaction and clinical symptoms in human subjects exposed to nasal allergen provocation. The number of subjects for Study No. 2 will be determined based on the findings in the pilot *in vitro* and clinical study..
- 30

Hypotheses

There is evidence that nasal allergen provocation of atopic individuals induces systemic effects, e.g., peripheral blood eosinophil counts are increased between 6 to 24 hours following this procedure and consistent increases in lower airway responsiveness, in patients with allergic rhinitis and asthma, have followed nasal allergen provocation. It is possible that the systemic effects of allergic rhinitis are mediated through increased proliferation of peripheral leukocytes and increased cytokine production by these cells. The underlying rationale for these hypotheses is that these phenomena are dependent on the state of activation in immune cells, including basophils and lymphocytes.

Study Design

The clinical efficacy will involve the same essential nasal allergen challenge design and blood specimen collections and allergen-induced skin wheal testing as in Study No. (See below.) Study No. 2, however, will be a double-blind, placebo-controlled, cross-over design during which desloratadine (5 mg once daily) and placebo will be taken daily for 5-7 days prior to the first blood drawing and throughout the remainder of the testing period: the repeat allergen-induced skin wheal test will occur one week after the last nasal allergen challenge. The number of subjects for this study will be determined by power analysis dependent on the results of the preliminary study. A two-week washout period will intervene between the two treatment periods.

Flow Chart (Study Days)

-3 (baseline)	0	1	2	9
• blood drawn	• nasal allergen challenge**	• nasal allergen challenge**	• nasal allergen challenge**	• skin wheal test
• skin wheal test	• blood draw* • dosing	• blood draw* • dosing	• blood draw* • dosing	• dosing → dosing

* • for leukocyte differential, total eosinophil and basophil counts

5 • for isolation of basophils and lymphocytes and extraction of their RNA for PCR assay (IL-4, IL-3, IL-13, IL-5, IL-6 and RANTES)

** clinical symptoms and severity scoring

Clinical Efficacy Endpoints

10 Comparisons of results will be made between *treatment* groups and *within* treatment groups for:

Changes from baseline in peripheral leukocytes, including eosinophils, basophils and lymphocytes.

15 Changes from baseline in cytokine production.

Changes from baseline in the size of the allergen-induced skin wheal late phase reaction.

20 Correlation of the above changes with clinical symptomatology,

Desloratadine is expected to provide combined anti-histamine and anti-allergic inflammatory effects to control both early and late phase allergic reactions and clinical symptoms in humans.

25

We claim:

- 1) A method of blocking and/or inhibiting generation of pro-inflammatory cytokines in a patient in need of such blocking and/or inhibiting which comprises administering to such a patient an effective amount of desloratadine.
- 2) The method of claims 1 wherein the pro-inflammatory cytokines are IL-4 and IL-13.
- 3) A method of inhibiting generation of IL-4 and IL-13 from human basophils in a patient exhibiting the symptoms of an allergic and/or inflammatory condition which comprises administering to such a patient an amount of desloratadine effective to inhibit the generation of IL-4 and IL-13 and to concurrently treat the symptoms of such an allergic and/or inflammatory condition.
- 4) A method of treating a disease state that has an allergic component and an inflammatory component which comprises administering to a patient in need of such treatment an amount of desloratadine effective to produce an anti-inflammatory effect.
- 5) The method of claim 4 wherein the disease state is allergic rhinitis, allergic asthma, atopic dermatitis, intestinal food allergies, or urticaria.
- 6) A method of treating and/or preventing an allergic and/or inflammatory condition and inhibiting secretion of IL-4 and IL-13 in a patient in need of such treating and/or preventing which comprises administering to such a patient an effective amount of desloratadine.

7) A method of treating IL-4 and IL-13 mediated disease states in a patient in need of such treating which comprises administering to such a patient an effective amount of desloratadine.

5 8) A method of claim 7 wherein effective amount of desloratadine is sufficient to inhibit generation of IL-4 and IL-13 from human basophils.

10 9) A method of inhibiting generation of IL-4 and IL-13 from human basophils in a patient exhibiting the symptoms of an allergic and/or inflammatory condition of the skin, eyes, intestinal tract, and/or the upper and lower airway passages which comprises administering to such a patient an amount of desloratadine effective to inhibit the generation of IL-4 and IL-13 and to concurrently treat the symptoms of such an allergic and/or inflammatory condition.

15

1012741_112741_1

ABSTRACT

Methods of inhibiting the generation of pro-inflammatory cytokines such as
5 IL-4 and IL-13 in a human patient in need of such inhibiting are disclosed.

FIGURE 1




FIG. 1a




FIG. 1b

2/5




FIG. 2




FIG. 3




FIG. 4

4/5




FIG. 5a




FIG. 5b




FIG. 5c




FIG. 5d

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00, OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☒ Declaration Submitted with Initial Filing OR ☐ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number AL01143K

First Named Inventor Schleimer

COMPLETE IF KNOWN

Application Number /

Filing Date April 24, 2001

Group Art Unit To Be Assigned

Examiner Name To Be Assigned

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

INHIBITION OF CYTOKINE GENERATION

☒ the specification of which (Title of the invention)

☒ is attached hereto

OR

☐ was filed on (MM/DD/YYYY) as United States Application Number or PCT International

Application Number and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name

Signature

Date

Express Mail Label No. BL403237585US

Date April 24, 2001

Please type a plus sign (+) inside this box ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 355(c) of any PCT International application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of this prior application and the national or PCT International filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (If applicable)

☐ Additional U.S. or PCT International application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: ☒ Customer Number 24265 ☐ Registered practitioner(s) name/registration number listed below

Place Customer Number Bar Code Label here

Name	Registration Number	Name	Registration Number

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☒ Customer Number or Bar Code Label 24265 OR ☐ Correspondence address below

Name	THOMAS D. HOFFMAN			Reg. No.	28,221
Address					
Address					
City		State		ZIP	
Country		Telephone	(908) 298-5037	Fax	(908) 298-5388

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the lies so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))		Family Name or Surname	
ROBERT P.		SCHLEIMER	
Inventor's Signature	<i>Robert P. Schleimer</i>		Date <u>4/9/01</u>
Residence: City	BALTIMORE	State	MD
		Country	U.S.A.
Post Office Address	704 STAGS HEAD ROAD		
Post Office Address			
City	BALTIMORE	State	MD
		ZIP	21286
		Country	U.S.A.

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → +

PTO/SB/02A (3-97)
Approved for use through 9/30/98. OMB 0851-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION	ADDITIONAL INVENTOR(S) Supplemental Sheet Page <u>1</u> of <u>1</u>
--------------------	---

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
JOHN		SCHROEDER	
Inventor's Signature	<i>John Schroeder</i>		Date 4/8/01
Residence: City	BALTIMORE	State MD	Country U.S.A.
Post Office Address 47 DUNMORE ROAD			
Post Office Address			
City	BALTIMORE	State MD	Country U.S.A.
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
WILLIAM		KREUTNER	
Inventor's Signature	<i>William Kreutner</i>		Date 4-4-01
Residence: City	WEST PATERSON	State NJ	Country U.S.A.
Post Office Address 18 WOODLAND DRIVE			
Post Office Address			
City	WEST PATERSON	State NJ	Country U.S.A.
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Inventor's Signature			Date
Residence: City		State	Country
Post Office Address			
Post Office Address			
City		State	Country

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.